Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

Core Viewpoint - Vaxcyte, Inc. is a clinical-stage vaccine innovation company focused on developing high-fidelity vaccines to combat bacterial diseases, with upcoming participation in the Guggenheim SMID Cap Biotech Conference [1] Company Overview - Vaxcyte is engineering broad-spectrum conjugate and novel protein vaccines aimed at preventing or treating bacterial infectious diseases [3] - The company is developing VAX-31, a 31-valent PCV for preventing invasive pneumococcal disease (IPD) in adults and infants, and VAX-24, a 24-valent PCV currently in Phase 2 infant study [3] - Both VAX-31 and VAX-24 aim to improve upon existing PCVs by covering serotypes responsible for high case-fatality rates and antibiotic resistance [3] Technology and Innovation - Vaxcyte utilizes modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, to produce complex vaccines more efficiently [4] - The company's approach is designed to enhance the immunological benefits of vaccines while accelerating the development process [4] Pipeline Candidates - Vaxcyte's pipeline includes VAX-A1 for preventing Group A Strep infections, VAX-PG for slowing periodontal disease progression, and VAX-GI for preventing Shigella [4]